TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06815991: Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

Sponsor: Metro International Biotech, LLC · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT06815991 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06815991 Rescue Dossier →